secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-022046
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx posts Q4 net income of $20.5M, cash $729.2M, expands Kite partnership
-----------------------------------------------------------------------------

- Q4 2023 net income $20.5M vs net loss $39.0M in Q4 2022; full-year net loss narrowed to $70.7M from $188.7M.
- Cash, cash equivalents and marketable securities $729.2M; cash runway extended into 2027.
- Collaboration revenue from Kite partnership: $63.1M in Q4 and $110.3M full year, both vs zero.
- Kite partnership expanded with $200M equity investment at $61.68/share and $85M upfront cash, plus co-development of anito-cel for lymphomas.
- Phase 1 anito-cel data: 100% ORR, 76% CR/sCR (29/38 patients), no delayed neurotoxicity, median DOR/PFS/OS not reached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017024022046/0000950170-24-022046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017024022046/aclx-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-022046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer